Cynosure Group LLC bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) in the first quarter, Holdings Channel.com reports. The firm bought 7,254 shares of the company’s stock, valued at approximately $319,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of AMPH. YHB Investment Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals during the 1st quarter valued at about $27,000. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Principal Securities Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $34,000. Quadrant Capital Group LLC lifted its position in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Amphastar Pharmaceuticals by 115.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after buying an additional 1,300 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Piper Sandler reissued an “overweight” rating and issued a $71.00 price objective on shares of Amphastar Pharmaceuticals in a report on Thursday, June 27th. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $66.00.
Insider Transactions at Amphastar Pharmaceuticals
In related news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares in the company, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,596 shares of company stock valued at $313,544. 27.10% of the stock is currently owned by corporate insiders.
Amphastar Pharmaceuticals Trading Up 1.0 %
AMPH traded up $0.40 on Tuesday, hitting $41.07. The company had a trading volume of 57,697 shares, compared to its average volume of 414,369. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88. The firm has a market cap of $2.01 billion, a P/E ratio of 14.18, a PEG ratio of 0.70 and a beta of 0.80. The company’s fifty day moving average price is $40.60 and its 200 day moving average price is $45.27. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $67.66.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. The company had revenue of $171.84 million for the quarter, compared to analyst estimates of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. As a group, equities analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.6 earnings per share for the current year.
Amphastar Pharmaceuticals Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Stories
- Five stocks we like better than Amphastar Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- What is a Death Cross in Stocks?
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- How Investors Can Find the Best Cheap Dividend Stocks
- Can This Meme Stock Stage One Last Rally?
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.